
    
      As is commonly done in a bioequivalence study, the null hypothesis is that the generic (i.e.
      test) is bioINequivalent to the brand name (i.e. reference). Hence, the alternative
      hypothesis is that the generic is bioequivalent to the brand name.
    
  